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Characterisation of drug‑resistant
Mycobacterium tuberculosis
mutations and transmission
in Pakistan
Gary Napier1, Anwar Sheed Khan2,3, Abdul Jabbar4, Muhammad Tahir Khan5, Sajid Ali6,
Muhammad Qasim2, Noor Mohammad2,3, Rumina Hasan1,7, Zahra Hasan7, Susana Campino1,
Sajjad Ahmad8, Baharullah Khattak2, Simon J. Waddell9, Taj Ali Khan8*, Jody E. Phelan1* &
Taane G. Clark1,10*
Tuberculosis, caused by Mycobacterium tuberculosis, is a high-burden disease in Pakistan, with multidrug (MDR) and extensive-drug (XDR) resistance, complicating infection control. Whole genome
sequencing (WGS) of M. tuberculosis is being used to infer lineages (strain-types), drug resistance
mutations, and transmission patterns—all informing infection control and clinical decision making.
Here we analyse WGS data on 535 M. tuberculosis isolates sourced across Pakistan between years 2003
and 2020, to understand the circulating strain-types and mutations related to 12 anti-TB drugs, as well
as identify transmission clusters. Most isolates belonged to lineage 3 (n = 397; 74.2%) strain-types,
and were MDR (n = 328; 61.3%) and (pre-)XDR (n = 113; 21.1%). By inferring close genomic relatedness
between isolates (< 10-SNPs difference), there was evidence of M. tuberculosis transmission, with
55 clusters formed consisting of a total of 169 isolates. Three clusters consist of M. tuberculosis that
are similar to isolates found outside of Pakistan. A genome-wide association analysis comparing
‘transmitted’ and ‘non-transmitted’ isolate groups, revealed the nusG gene as most significantly
associated with a potential transmissible phenotype (P = 5.8 × 10–10). Overall, our study provides
important insights into M. tuberculosis genetic diversity and transmission in Pakistan, including
providing information on circulating drug resistance mutations for monitoring activities and clinical
decision making.
Tuberculosis disease (TB), caused by bacteria in the Mycobacterium tuberculosis complex, is a major global public
health problem. Pakistan is a high-burden TB country, being one of eight countries accounting for two-thirds of
the estimated 10 million people globally that fell ill with the disease1. In 2019, Pakistan had ~ 570,000 TB cases
(incidence rate 263 per 100,000) and 43,900 deaths1, but disease control is being compromised by increasing
HIV prevalence and drug resistance. The country has a high burden for rifampacin resistant (RR-TB), as well
as multidrug-resistance (MDR-TB), which is the additional resistance to isoniazid treatments. Pre-extensive
drug resistance (pre-XDR-TB) is prevalent1,2, involving M. tuberculosis that are MDR-TB and resistant to any
fluoroquinolone or at least one of the three second-line injectable drugs (capreomycin, kanamycin, amikacin).
XDR-TB requires resistance to any fluoroquinolone and a second-line injectable. In January 2021, WHO updated
these definitions of XDR-TB to include other drugs, such as bedaquiline3. Here, we adopt the older version of
1

Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London,
UK. 2Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan. 3Laboratory
Hayatabad Medical Complex, Provincial Tuberculosis Reference, Peshawar, Pakistan. 4Department of Medical
Lab Technology, University of Haripur, Haripur, Pakistan. 5Institute of Molecular Biology and Biotechnology, The
University of Lahore, KM Defence Road, Lahore 58810, Pakistan. 6Institute of Biotechnology and Microbiology,
Bacha Khan University, Charsadda, Pakistan. 7Department of Pathology and Laboratory Medicine, The Aga
Khan University, Karachi, Pakistan. 8Institute of Institute of Pathology and Diagnostic Medicine, Khyber Medical
University, Peshawar, Khyber Pakhtunkhwa, Pakistan. 9Global Health and Infection, Brighton & Sussex Medical
School, University of Sussex, Falmer BN1 9PX, UK. 10Faculty of Epidemiology and Population Health, London
School of Hygiene and Tropical Medicine, London, UK. *email: tajalikhan.ibms@kmu.edu.pk; jody.phelan@
lshtm.ac.uk; taane.clark@lshtm.ac.uk
Scientific Reports |

(2022) 12:7703

| https://doi.org/10.1038/s41598-022-11795-4

1
Vol.:(0123456789)

www.nature.com/scientificreports/
the definition as the underlying cases were treated within that framework. There were ~ 25,000 cases of MDR-/
RR-TB in 2 0191. The National TB control program aims to reduce by half the prevalence of TB in the general
population by 2025, but to achieve this will require the scaling-up of TB detection and clinical care, as well as
improved systems for inferring disease transmission, thereby facilitating further targeted interventions.
Whole genome sequencing (WGS) is revolutionizing our understanding of drug resistance and clinical management, as well as transmission patterns, thereby assisting disease c ontrol4. M. tuberculosis drug resistance is
linked to genomic variants in drug targets or pro-drug activators, including single nucleotide polymorphisms
(SNPs) and small insertions and deletions (indels), some occurring in gene–gene interactions. It is therefore
possible to predict resistance genotypically for 19 anti-TB drugs and their groups (e.g. floroquinolines) using
curated libraries of > 1000 mutations across > 30 l oci5,6, thereby personalizing treatment. Genotypic predictions
are an alternative to bacterial culture-based phenotypic drug susceptibility testing (DST), which can be timeconsuming and resource intensive, with reproducibility and inhibitory concentration cut-off challenges for
particular drugs5. Further, WGS data infers the population structure within the M. tuberculosis complex, which
is phylo-geographical in nature, with strains falling within distinct (sub-)lineages7, and potential transmission
chains identified through isolates with (near-)identical genomic v ariation8. The identification of highly virulent
strain-types or lineages, drug resistance, and transmission clusters will assist the targeting of limited resources
for TB control.
There have been recent studies using WGS to characterize M. tuberculosis genetic diversity in isolates sourced
from Pakistan, where the predominant strains are from the Central Asian (CAS) family, set within lineage 32,9–13.
A recent study of TB endemic province of Khyber Pakhtunkhwa (North West Pakistan) found that known mutations in rpoB (e.g. S405L), katG (e.g. S315T), or inhA promoter loci explain the majority of MDR-TB, but there
was evidence of complex mixed infections and heteroresistance, which may reflect the high transmission nature
of the s etting13. An earlier study in the same province found similar MDR-TB mutations, but also additional
variants in genes conferring resistance to other first and second-line drugs, including in pncA (pyrazinamide),
embB (ethambutol), gyrA (fluoroquinolones), rrs (aminoglycosides), rpsL, rrs and gid (streptomycin) loci. Further, acquisition of rifampicin resistance often preceded isoniazid in these isolates, and a high proportion (~ 18%)
of pre-MDR isolates had fluoroquinolone resistance markers, being a class of antibiotics that is widely available
and used2. Eighteen M. tuberculosis isolates clustered within eight networks, thereby providing evidence of drugresistant TB transmission in the Khyber Pakhtunkhwa p
 rovince2. An investigation of XDR-TB isolates sourced
across four provinces in Pakistan found similar genes linked to drug resistance as in Khyber Pakhtunkhwa11,
and an increased frequency and expression of novel SNP mutations in efflux pump genes, potentially explaining
some drug resistance11.
Here, we analyse 535 M. tuberculosis samples with WGS data, collected between years 2003 and 2020, with
phenotypic testing of resistance across 12 drugs (rifampicin, isoniazid, ethambutol, pyrazinamide, streptomycin,
ofloxacin, moxifloxacin, amikacin, kanamycin, capreomycin, ciprofloxacin, ethionamide). By identifying ~ 38 k
SNPs, and inferring genotypic drug resistance across 19 anti-TB drugs (as well as fluoroquinolone and aminoglycoside classes), we sought to understand the phylogeny of M. tuberculosis in the largest Pakistan dataset,
identify transmission events, and infer commonly circulating mutations linked to drug resistance. The genetic
insights were validated in a large M. tuberculosis collection (n = 34 k) with WGS and drug susceptibility test d
 ata7.

Results

Isolates and whole genome sequencing data. A total of 535 M. tuberculosis isolates sourced between
years 2003 and 2020 from Pakistan with publically available WGS and phenotypic susceptibility testing were
analysed2,9–13. These isolates covered at least four provinces (Balochistan, Khyber Pakhtunkhwa, Punjab, Sindh),
but a high proportion of locations were missing (69.5%), all from one s tudy12 (Table 1). The majority of samples
were from lineage 3 (L3 397, 74.2%; CAS strains), but the other main lineages were represented (L4, 80, 15.0%,
including LAM, T and X strains; L2 36, 6.7%, including Beijing; L1 22, 4.1%) (Table 1; S1 Table).
As expected phenotypic drug susceptibility testing (DST) was performed most often for first-line rifampicin
(n = 487, 91.0%), isoniazid (n = 487, 91.0%), ethambutol (n = 479, 89.5%), and pyrazinamide (n = 444, 83.0%)
(S2 Table). A total of 432 samples (80.7%) were phenotypically resistant to at least one drug (median 3, maximum 10). The number of potential errors on the phenotypic testing appeared modest (218/2430 tests, 9.0%),
where established genotypic resistance markers were present in isolates with DST results that implied drug
susceptibility. The discordance appeared for nine drugs, but more than half occurred in two drugs (ethambutol
96; pyrazinamide 42) (S2 Table). The majority of isolates were genotypically assessed as MDR-TB (328, 61.3%),
with proportions of (pre-) XDR (113, 21.1%) and pan-sensitive (60, 11.2%) (Table 1). There were 31 pre-MDR
isolates, and overall there was a high prevalence of rifampicin (460, 86.0%) and isoniazid (435, 81.3%) resistance
associated mutations. Resistance to other drugs was also detected, including ethambutol (385, 72.0%), pyrazinamide (258, 48.2%), streptomycin (238, 44.5%), ethionamide (102, 19.1%), any fluoroquinolone (277, 51.8%)
or aminoglycoside (75, 14.0%). Very few isolates appeared resistant to bedaquiliine, clofazimine and cycloserine
(n < 3; Table 1). Across all lineages, the majority of isolates (> 75%) were at least MDR-TB resistant (S3 Table).
After sequence data alignment, high average coverage was observed across the samples (median 76-fold,
range 30—2027 fold). Across the isolates, a total of 37,970 genome-wide SNPs were identified, with 23,741
(62.5%) found in single samples. A phylogenetic tree constructed using the 37,970 genome-wide SNPs revealed
the expected clustering by lineage (Fig. 1; S1 Figure).
Evidence of transmission. The median (range) pairwise SNP differences across the 535 isolates was 390

(minimum 0, maximum 1811), with a multi-modal distribution, where modes represent differences within and
between lineages (S2 Figure). At a threshold of 10 SNPs, 55 clusters formed consisting of a total of 169 isolates,
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Characteristic

Lineage

Drug resistance status

a

Individual drug resistancea

Collection year

Region

Group

N

1

22

%
4.1

2

36

6.7

3

397

74.2

4

80

15.0
11.2

Sensitive

60

Pre-MDR

31

5.8

MDR

328

61.3

Pre-XDR

47

8.8

XDR

66

12.3

Other

3

Rifampicin

460

0.6
86.0

Isoniazid

435

81.3

Ethambutol

385

72.0

Pyrazinamide

258

48.2

Streptomycin

238

44.5

Ofloxacin

277

51.8

Moxifloxacin

277

51.8

Levofloxacin

277

51.8

Amikacin

75

14.0

Kanamycin

79

14.8

Capreomycin

78

14.6

Ciprofloxacin

277

51.8

Ethionamide

102

19.1

Para aminosalicylic acid

10

1.9

Cycloserine

2

0.4

Clofazimine

1

0.2

Bedaquiline

1

0.2

Fluoroquinolones

277

51.8

Aminoglycosides

75

14.0

2003—2005

49

9.2

2015—2017

438

81.9

2018—2020

48

9.0

Peshawar

77

14.4

Dera Ismail Khan

25

4.7

Abbottabad

13

2.4

Swat

13

2.4

Rawalpindi

7

1.3

Hyderabad

5

0.9

Karachi

5

0.9

Lahore

5

0.9

Other

13

2.4

Missing

372

69.5

Table 1.  Mycobacterium tuberculosis samples (N = 535). a Genotypic prediction using TB-Profiler.

where the median number of isolates in each cluster was 2 (range: 2—22) (S2 Figure). By reducing the cut-off
to 5 SNPs, there were only 6 less clusters (total 49) consisting of a total of 33 isolates (overall 136 isolates) (S4
Table). The 169 transmitted isolates (SNP cut-off 10) were found in three of the four provinces recorded (Khyber
Pakhtunkhwa 71/169; Punjab 9/169; Sindh 9/169), identified across all lineages (L1 7/169, L2 21/169, L3 98/169,
L4 43/169) and in (pre-)XDR (75/169) samples (S3 Figure; S4 Figure). Most clusters had samples with the same
drug resistance phenotype (44/55), and there was some evidence of clusters consisting of more than one location
(35/55, excluding missing locations) (S3 Figure; S4 Figure). Comparing the 169 "transmitted" isolates in clusters
to the others ("non-transmitted"; n = 366), there were overall differences in lineage (Chi-Square, P < 6 × 10–8) and
drug resistance (Chi-square P < 5 × 10–15). Specifically, there was marginally weak evidence of an increased risk
of transmission in lineage 2 (odds ratio (OR) = 3.00, P = 0.054) and lineage 4 (OR = 2.49, P = 0.073), compared
to lineage 1. Signals of increased risk of transmission were stronger among those pre-XDR/XDR (OR = 5.79,
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Figure 1.  A phylogenetic tree for the 535 M. tuberculosis isolates constructed using 37,970 SNPs. The
surrounding rings of data for each isolate include: lineage (inner), drug resistance status, location, and
transmission status (outer).

P < 5 × 10–14), compared to a less resistant status. There was no association between transmission risk and province (Chi-Square P = 0.64), but there were high levels of missing location data (S5 Table).
A genome-wide association study (GWAS) approach was applied to detect loci potentially linked to transmissibility. It revealed nusG, Rv2307B, wag31, proX and murA genes to be the most associated with being in a
transmission cluster (P < 10–5) (S6 Table). Rv2307 (beta = 0.745, P = 1.5 × 10–8) putatively codes for a glycine rich
protein, while proX (beta = 0.706, P = 1.3 × 10–6) encodes osmoprotectant binding lipoprotein ProX. There were six
mutations found in each of these genes, although no clear pattern relating to either phylogenetic or transmission
status could be discerned, with mutations found in both transmission and non-transmission samples, as well as
many samples having more than one of these mutations. The nusG (beta = 0.791, P = 5.8 × 10–10) encoded protein
participates in transcription elongation, termination and anti-termination. There are five key mutations (S206G,
E186A, R124L, A161V, F232C). By locating their position on a phylogenetic tree, only R124L was supported
by isolates in more than one clade (S5 Figure). The wag31 gene (beta = 0.912, P = 3 × 10–7) codes for a cell wall
synthesis protein, but only one mutation (G67S) was associated with a single small transmission clade (n = 5) (S5
Figure). The murA gene codes for a peptidoglycan biosynthesis pathway, and had five mutations (E226K, R247L,
D318A, H394Y, E414K), but none were found in more than one clade and only two mutations overlapped with
transmission samples (H394Y, E226K) (S5 Figure).
The transmission clusters involved six main sub-lineages (1.1.2, 2.2.1, 3, 3.1.2, 4.5, 4.9), and we looked for
similar isolates in other populations within the global 34 k dataset. Using a more relaxed cut-off of 20 SNPs difference to allow for greater time between transmission events, three of the sub-lineages (3, 2.2.1, 4.5) revealed
similar isolates collected from other countries (Fig. 2). Lineage 2.2.1 had 19 Pakistan isolates linked to 29 global
samples, mostly from countries in Europe and Central Asia. Lineage 3 had 8 Pakistan isolates linked to 5 other
samples from the UK, while sub-lineage 4.5 had two Pakistan samples linked to a single isolate from the UK.
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Figure 2.  Phylogenetic trees for sub-lineages involving Pakistan samples and closely-related global isolates from
previously published datasets. (a) Sub-lineage 2.2.1 (19 Pakistan, 25 other). (b) Lineage 3 (8 Pakistan, 4 UK).
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Drug

N

Gene

Change [N]

Aminoglycosides

129

rrs

1401a > g [74], 514a > t [3], 906a > g, [2], 1484g > t [1], 514a > c [47], 905c > g [2], 517c > t [8]

Capreomycin

3

tlyA

198_198del [1], N236K [2]

Cycloserine

2

alr

M343T [1], L113R [1]

embA

−12C > T [19], −16C > G [2], −16C > T [12], −11C > A [5]

Ethambutol

385

embB

G406A [13], G406S [8], M306I [132], G406D [22], G406C [6], Q497R [20], Q497K [9], Q497P [2], Q853P [2], E405D [1], E504D [2],
A313V [1], M306L [20], M306V [127], Y319C [1], Y319S [1], Y334H [2], S347I [1], D354A [7], D1024N [29], D328Y [3]

ethA

1200_1201del [1], 1054_1054del [1], 599_599del [1], 1261_1262insCGAGC [1], 1018_1018del [1], 1047_1047del [1], 1300_1301insGT
[1], 61_61del [1], 671_671del [1], 1290_1291insC [1], 4326936_4328449del [5], 4326943_4328449del [1], 4326944_4328449del [1],
4327038_4327099del [1], Q269* [4], Q347* [6], L272P [1], L397R [2], T61M [1], 672_673insG [2], 673_674insGC [1], 140_140del [3],
150_150del [1], 299_299del [3], 313_319del [1], 352_365del [2], 382_383insG [4], 392_392del [2], 404_405insAT [1], 703_703del [1],
755_756insGC [2], 825_825del [1]

gyrA

G88A [1], G88C [3], D89N [4], A90V [68], S91P [21], D94G [128], D94A [19], D94H [4], D94Y [17], D94N [24]

Ethionamide

54

Fluoroquinolones

277

Isoniazid

416

Kanamycin

5

Pyrazinamide

Rifampicin

Streptomycin
INH, Ethionamide

258

460

172
58

PAS

10

BDQ, CFZ

1

gyrB

R446C [1], S447F [5], I486L [1], T500N [3], E501D [4]

katG

22_23insA [1], 238_260del [1], 337_337del [1], 679_680insGC [1], 87_87del [1], 974_974del [1], 2148451_2164815del [1],
2149885_2172950del [1], 2151318_2157225del [1], 2152294_2157889del [1], A172V [1], R104Q [1], D259E [1], G297V [1], S140N [2],
S315N [8], S315I [1], S315T [365], T275A [2], T380I [3], W191R [2], W328S [1], Y155C [1], Y155S [2], Y337C [1], Y413H [1], V1A [2],
1176_1177insG [1], 1196_1197insGA [1], 1284_1284del [1], 1328_1328del [1], 1486_1487insC [1], 2005_2006insG [2], 58_58del [1],
58_59insCT [1], 596_596del [1], 371_371del [1], 60_61insGT [1]

ahpC

−54C > T [4], −81C > T [2]

eis

−10G > A [1], −14C > T [3], −37G > T [1]

pncA

−11A > C [4], −11A > G [15], −12 T > C [1], 108_108del [1], 13_14insGA [1], 166_167insG [1], 194_203del [1], 206_207insC [1],
209_210insACC [1], 226_236del [1], 230_231insA [1], 283_283del [1], 314_315insG [2], 346_347insC [2], 377_378insGA [1], 382_383insG
[1], 391_392insG [2], 391_392insGG [17], 393_394insC [1], 408_409insT [1], 412_413insCATT [1], 417_418insG [3], 424_425insGA [2],
429_429del [1], 430_431insG [1], 438_439insCG [1], 455_456insATGGCTTGGC [2], 501_502insC [1], 53_53del [1], 61_62insG [1], 7_7del
[1], 2285437_2291074del [1], 2288627_2289103del [2], 2288776_2288836del [1], 2288825_2289242del [1], 2289006_2290299del [1], A134V
[1], A143D [1], A146V [2], A171T [4], A3E [2], R140G [4], D12A [3], D136Y [1], D49N [1], D49G [1], D63G [1], D63H [4], C14R [1],
C72Y [1], Q10* [1], Q10R [5], Q10P [5], Q141P [4], G105D [1], G108R [1], G132S [3], G78S [4], G78V [1], G97S [3], H51Q [1], H57P [1],
H57Y [4], H71R [3]. H71Y [3], H82R [1], I133T [2], I31S [1], I5T [2], I6M [1], I6T [1], L156P [1], L159R [2], L19R [2], L27P [1], L35P [1],
L4S [2], L4W [1], L85P [1], K96R [2], K96E [1], K96T [2], M175T [2], M1T [1], F58L [1], F94L [1], P54L [23], P62L [2], P62S [2], P69R [3],
S104R [1], S164P [1],S67P [4], T100I [1], T135P [4], T142A [1],T142M [1], T160P [3], T47P [3], T61P [1], T76I [2], T76P [6], W119R [3],
W68* [1], W68R [2], W68C [3], W68G [2], W68S [1], Y103C [1], Y34S [1], Y41* [1], V128G [1], V139A [4], V139G [1], V180F [8], V45G
[1], V7F [2], V9G [2]

rpoB

1296_1297insTTC [2], 1306_1308del [3], A286V [2], N437Y [1], D435G [5], D435F [2], D435Y [30], D435V [32], Q429H [2], Q432H [1],
Q432L [3], Q432K [4], Q432P [1], H445R [2], H445N [8], H445D [6], H445C [2], H445Q [2], H445L [9], H445P [2], H445Y [11], I480V
[1], I491F [1], L430R [3], L430P [8], L452P [12], M434I [11], S428R [1], S428T [1], S441Q [1], S441L [2], S450L [293], S450F [2], S450W
[9], S450Y [1], S493L [1], T400A [1], T444I [1], V170F [2]

rpoC

D747A [1], G332R [6], I491T [13], I885V [1], L527V [5]

gid

102_102del [2], 115_115del [3], 351_351del [4], 4407713_4407860del [1], A80P [3], L79S [1]

rpsL

K43R [126], K88R [21], K88M [1], K88T [2]

fabG1

−15C > T [52], −17G > T [1], −8 T > A [1], −8 T > C [4]

inhA

I194T [4], I21T[1], S94A [4], I21V [1]

folC

E153A [1], I43S [5], R49W [1], I43T [1]

thyX

−16C > T [2]

mmpR5

192_193insG [1]

Table 2.  Number of samples with known drug resistance-associated mutations. BDQ bedaquiline, CFZ
clofazimine, INH isoniazid, PAS para aminosalicylic acid. *Premature stop codon.

Drug resistance mutations. The common mutations underlying genotypic drug resistance were in

known loci. These included mutations in rpoB (D435GFYV 293/460, S450LFWY 308/460) linked to rifampicin,
katG (S315NIT 374/416) and fabG1 (−15C > T 52/416) linked to isoniazid, embB (G406ASDC 51/385, M306ILV
280/385, Q497RKP 40/385) linked to ethambutol, gyrA (A90V 68/277, S91P 22/277, D94GAHYN 195/277)
linked to fluoroquinolones, and pncA (118 low frequency < 25/258) linked to pyrazinamide (Table 2). A high
proportion of mutations detected were present in the global 34 k dataset, including pncA 93/118, katG 19/38,
rpoB 37/39, and embB 21/21. Nearly half all mutations identified (156/313) were present in single isolates, of
which the majority were in the 34 k dataset (101/156) and absent from sensitive strains (S7 Table).
We investigated isolates that had a DST implying resistance, but no established genetic mutations to explain
this phenotype. There were 82 isolates (100/2430 tests; (S2 Table)) with this discordance across 9 drugs (amikacin (9), capreomycin (2), ciprofloxacin (4), ethambutol (17), isoniazid (25), kanamycin (7)), pyrazinamide (24),
rifampicin (6), streptomycin (6)). We identified 68 distinct genetic markers in candidate genes to potentially
explain the discordance (Table 3). Twenty-nine (42.6%) mutations had strong evidence of being linked with
drug resistance, including from functional consequences, homoplasy or global data information7,14. Forty-six
(67.6%) mutations were present in the global 34 k dataset, and all of these were absent in sensitive strains (S8
Table), reinforcing them as putatively resistant related.
For rifampicin resistance, we identified three inframe indels in rpoB (1291_1292insGCC, 1294_1296del and
1309_1311del) in three isolates. For isoniazid, several nonsense mutations in katG were found, with 3 mutations
leading to premature stop codons (W438*, W204*, Q36*) and a frameshift mutation (587_588insGGT). For ethambutol resistance, variants in the embA promoter region (−42CAT > C, −27TA > T-16C > A, −8C > A) and embB
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Drug

Gene

Amikacin

rrs

−92 T > G [1], 878 g > a [2]

gyrA

A288D [1]

gyrB

−162C > CG [1], A432V [1]

embA

−16C > A [2], −27TA > T [1], −42CAT > C [1], −8C > A [1], P455Q [1], V534A [1]

embB

R524H [1], D328H [1], D328F [2], L172R [2], F330L [1], T546I [1]

ubiA

G268D [1], F238I [1], V188L [1]

ahpC

−52C > A [1], −72C > T [1], −76 T > A [4], −76 T > C [1], −76 T > G [1], −93G > A [1]

Ciprofloxacin

Ethambutol

Isoniazid

Kanamycin

Pyrazinamide

Change [N]

kasA

M72I [1], F402I [1]

katG

587_588insGGT[1], A122D [1], A348G [1], R484G [1], D189Y [1], Q36* [1], G186D [1], G299D [1], I103V
[1], L298S [1], M105I [1], F408S [1], P100T [1], T271I [1], T475I [1], T625K [1], W204* [1], W438* [1], Y197D
[1]

eis

L386I [1]

rrs

−92 T > G [1]

pncA

−7 T > G [1], 392_393insGGT[1], 451_462del [1], 511_512insTCGCCG [1], L120R [4], P62T [1], P69T [1],
S18* [1], V130M [1], V180A [1]

rpsA

−98A > T [1], Q410R [2]

Rifampicin

rpoB

1291_1292insGCC[1], 1294_1296del [1], 1309_1311del [1]

Streptomycin

gid

A119D [1], A82P [1], D67G [1], G71* [2]

Table 3.  Putative novel drug resistant mutations. *Based on absence in the curated TB-Profiler mutation list;
bolded, if not observed in a large TB Global dataset (34 k7); underlined, if with multiple levels of evidence for
drug resistance (see S8 Table).

were observed. For pyrazinamide resistance, several potentially new mutations were found in pncA, including
three inframe indels (511_512insTCGCCG, 392_393insGGT and 451_462del), a premature stop codon (S18*),
and SNPs in both the coding region (Val180Ala) and the promoter (−7 T > G). For streptomycin resistance,
several mutations were found in gid including a premature stop codon (G71*), a frameshift (102_102del), and
SNPs (A119D, A82P and D67G). These SNPs were found in the 34 k global dataset, and likely acquired as the
result of homoplasy. The gid A119D mutation was present in 15 isolates (ten different sublineages), of which two
had DSTs that reported resistance. The gid A82P mutation was present in three isolates from two different sublineages, but no DST data was available for these samples. The gid D67G was present in 38 global isolates from
five different sublineages. Of these, seven isolates had DST data available with four presenting with resistance.
For second line injectables, the rrs 878g > a mutation (seen previously2) was observed in four lineage 3 strains
with three independent homoplastic acquisitions, indicating it is unlikely to be strain-specifc. Mutations in rrs
are generally clustered in two regions with the most common mutations involved with streptomycin resistance
being located around position 514 and those involved with resistance to amikacin, kanamycin and capreomycin
located around 1401. The rrs 878g > a falls between the two mutation hotspots, and of the three strains which
had DST data (amikacin and kanamycin) in this study, two were resistant to both amikacin and kanamycin and
the other was sensitive to both. For fluoroquinolones, the gyrA A288D mutation was found in three lineage 3
isolates and was acquired in each sample independently. One isolate tested resistant to ciprofloxacin with no
known resistance mutation found in the gyrA and gyrB genes.

Discussion

The use of whole genome sequencing as a diagnostic is gaining traction in low resource and high TB burden
settings, where it has the potential to have greater public health impact5,7,15. Portable sequencing platforms and
multiplexing of M. tuberculosis isolates are making the application of WGS, both timely and cost e ffective5. Our
findings in the largest analysis of isolates from Pakistan to date revealed that lineage 2 and 4 strains, which are
pre-XDR and XDR-TB, are potentially being transmitted in the country. Evidence of increased transmission
among lineages 2 and 4 is consistent with previous characterisations of these clades as more transmissible7, and
therefore their strain-types should be monitored more closely despite greater prevalence of lineage 3. It is surprising that pre-XDR and XDR-TB samples were found to be clustered more than expected compared to MDR-TB
isolates given the usual fitness cost of drug resistance. This observation suggests that compensatory mutations
ought to be investigated in future work. Similarly, the finding that mutations in nusG, Rv2307B, wag31, proX
and murA genes maybe associated with transmission should be followed-up experimentally, where those with
variants appearing in more than one clade could be priortised. Advances in the characterisation of transmission
events16, GWAS9,17 and machine learning methods18,19 could enhance the ability to detect mutations linked to
transmissiblility. However, host factors and host–pathogen genetic interactions are also likely to be important.
More broadly, the routine collection, processing and WGS of M. tuberculosis DNA across Pakistan will provide
robust insights into mutations underlying drug resistance and geo-temporal dynamics.
Whilst our study uses a convenience sample that is not necessarily representative of the proportions of
MDR-TB in the wider Pakistan population, it is enriched by the presence of many mutations that lead to drug
resistance. The enrichment of drug resistant isolates from endemic TB regions with high transmission will reveal
important resistance mutations, including potential novel variants. To investigate the underlying mechanisms
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of drug resistance, we compared susceptibility profiles from phenotypic methods and genotypic prediction.
This analysis led to the identification of a number of potential new drug resistance mutations, including in
genes causing resistance to rifampicin, isoniazid, ethambutol and pyrazinamide. Three inframe deletions were
found in the rifampicin resistance determining region of rpoB. Inframe deletions have not been widely reported
as a major mechanism of resistance to rifampicin and it is surprising to see a relatively high number of these
mutations in our dataset. Previously unreported nonsense mutations were also found in the katG gene, a locus
responsible for resistance to isoniazid. A novel nonsense mutation, frameshift and inframe indels were found
in the pncA gene, which codes for the activator of pyrazinamide. Mutations in the promoter region of the pncA
gene lead to changes in the expression of PncA and r esistance20. The identified −7 T > G promoter mutation is
thus likely to cause resistance. However the functional effects of SNPs found in the coding region of pncA are
more difficult to p
 redict20. The pncA V180A mutation has been reported previously to be associated with pyrazinamide resistance20. For streptomycin, we observed several point mutations and a premature stop codon in the
gid gene. The gid D67G mutation was found in 38 isolates in the 34 k global dataset7, of which 57% of those were
phenotypically resistant to streptomycin. The incomplete penetrance of the streptomycin-associated gid D67G
mutation could be explained by the relative low-level resistance conferred by mutations in gid, which could be
below established critical cut-offs of minimum inhibitory concentration for susceptibility phenotyping, but still
elevated with respect to wild-type.
Overall, our work reinforces that the adoption of WGS platforms as a diagnostic tool, combined with mutational databases of drug resistance markers, will inform clinical decision making. The ability to perform WGS
for genomic investigations across time and geography will improve the understanding of transmission dynamics, and inform control programmes to reduce disease burden. The benefits will be greatest in high prevalence
TB settings, typically low and middle income countries, such as Pakistan. Although WGS is not currently at
a viable level of affordability, it is anticipated that amplicon and whole genome approaches using (portable)
next generation platforms will shortly become simple, affordable and accessible rapid diagnostics compared
to traditional laboratory-based methods that currently require specialist training, equipment and long culture
times. Importantly, there is evidence that WGS is more detailed and accurate in its profiling of drug resistance
than traditional DST, thereby likely to improve treatment and mortality outcomes in drug-resistant TB in highburden countries21.

Methods

Sequence data and processing.

WGS were sourced across six studies2,9–13 (ENA accessions: PRJEB7798,
PRJEB10385, PRJEB25972, PRJEB32684, PRJEB43284), where contributing isolates belong to a single patient.
Phenotypic DSTs were conducted using WHO endorsed methods, as specified in descriptions of the original
studies2,9–13. Raw reads were trimmed to remove low-quality sequences in Trimmomatic (v0.39)22, and aligned
to the H37Rv reference genome (AL123456) with BWA mem (v0.7.17)23. SNPs and indels called by samtools
software24 were processed using gatk GenotypeGVCFs (v4.1.3.0) (gatk.broadinstitute.org). Monomorphic SNPs
and variants in non-unique regions of the genome (e.g. pe/ppe genes) were excluded. A multi-FASTA format file
was created from the filtered SNP file and H37Rv reference fasta using bedtools makewindows (v2.28.0)25. This
multiple alignment was used to construct a phylogenetic tree with IQ-TREE (v1.6.12), involving a general time
reversible model with rate heterogeneity set to a discrete Gamma model and an ascertainment bias correction
(parameters −m GTR + G + ASC), with 1000 bootstrap s amples26. Pairwise distance matrices were calculated in
Plink software (v1.90b4)27. Drug resistance and lineages were predicted in silico from raw sequence data using
TB-Profiler (v2.4)5. The Pakistan analysis results were compared to a global collection of 34 k M. tuberculosis
with WGS and DST data7.
A cut-off of 10 SNPs difference was established to define transmission clades, and label samples as “transmitted” or “non-transmitted”. A sensitivity analysis was performed to assess the impact of changing the cut-off.
Linear mixed models were used perform a GWAS of transmissibility using SNPs, location, drug resistance and
adjusting for M. tuberculosis (sub-)lineage and outbreak-based population structure, being implemented in
GEMMA (v.1.1.2) (http://www.xzlab.org/software.html). We report association p-values less than a Bonferroni
cut-off based on testing 4,000 genes (P < 1.25 × 10–5). To identify if samples involved in transmission clades (> 10
samples) were similar to others (< 20 SNPs) in the global dataset (n = 34 k)7, we constructed phylogenetic trees
using FastTree for the relevant sub-lineages (1.1.2, 2.2.1, 3, 3.1.2, 4.5, 4.9). The likelihoods of ancestral locations
were inferred with the ape (v5.0) and phytools packages in R.
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